Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
675 participants
OBSERVATIONAL
2020-02-26
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Urinary Biomarkers for the Detection of Prostate Cancer
NCT05454371
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT02594202
Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer
NCT04702633
Markers for Early Detection of Prostate Cancer
NCT00340717
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
NCT00373035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To detect prostate cancer cells, shed in voided urine, using the optical imaging method developed in our laboratory, which targets vasoactive intestinal polypeptide receptor 1 (VPAC1) receptors expressed on prostate cancer cells and validates the results with prevailing condition of the patients/volunteers and evaluate diagnostic accuracy.
SECONDARY OBJECTIVES:
I. To establish if the malignant cells as a percent of total cell shed in the urine.
II. To establish the fluorescence intensity around malignant cells. III. To establish if the VPAC protein quantity in shed malignant cells correlate with the aggressiveness of the disease.
OUTLINE:
Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (biospecimen collection)
Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
Biospecimen Collection
Undergo collection of urine samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen Collection
Undergo collection of urine samples
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male
* Patients must be 50-70 years of age
* Willing to comply with all study procedures
* Prior to digital rectal exam (DRE)
* Patients with the diagnosis of prostate cancer (Cohort 1 N=150)
* Prior to radical prostatectomy/radiotherapy (XRT) or systemic therapy
* May be on active surveillance
* Patients with elevated PSA level but no know prostate cancer (Cohort 2 N=150)
* Diagnosis of BPH/lower urinary tract symptoms (LUTS)
* No prior diagnosis of prostate cancer
* Prior negative biopsy with PSA \> 1.5
* Without biopsy PSA \< 1.5
* Patients with normal PSA levels (Cohort 3 N=200)
* No documented history of BPH (no medical management or prior surgical treatment for BPH)
* PSA \< 1.5
* No documented history of prostate cancer
* No documented history of urothelial carcinoma
* Patients Pre DRE and Post DRE (Cohort 4 N=200)\*\*
* Patients on with a known Gleason Score (Cohort 5= 150)
Exclusion Criteria
50 Years
79 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Jefferson University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Madhukar Thakur, MD
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JT 15161
Identifier Type: OTHER
Identifier Source: secondary_id
20G.196
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.